Cargando…

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study

OBJECTIVES: To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA). METHODS: RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, A, Gladman, D, van der Heijde, D, Purcaru, O, Mease, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283690/
https://www.ncbi.nlm.nih.gov/pubmed/24942382
http://dx.doi.org/10.1136/annrheumdis-2014-205198
_version_ 1782351305479553024
author Kavanaugh, A
Gladman, D
van der Heijde, D
Purcaru, O
Mease, P
author_facet Kavanaugh, A
Gladman, D
van der Heijde, D
Purcaru, O
Mease, P
author_sort Kavanaugh, A
collection PubMed
description OBJECTIVES: To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA). METHODS: RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed the impact of PsA on paid work and household productivity, and participation in social activities during the preceding month. WPS responses were compared between treatment arms using a non-parametric bootstrap-t method. RESULTS: At baseline, 56.6%, 60.1% and 61.5% of placebo, CZP 200 mg Q2W and CZP 400 mg Q4W patients were employed. By week 24, employed CZP patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05). Within the home, by week 24, CZP patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05). CZP patients also reported fewer days with reduced household productivity or days lost for participation in family, social and leisure activities. Improvements with CZP were seen as early as week 4 and continued to week 24. CONCLUSIONS: CZP treatment significantly improved productivity at paid work and within the home, and resulted in greater participation in social activities for PsA patients. TRIAL REGISTRATION NUMBER: NCT01087788.
format Online
Article
Text
id pubmed-4283690
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42836902015-01-08 Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study Kavanaugh, A Gladman, D van der Heijde, D Purcaru, O Mease, P Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA). METHODS: RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed the impact of PsA on paid work and household productivity, and participation in social activities during the preceding month. WPS responses were compared between treatment arms using a non-parametric bootstrap-t method. RESULTS: At baseline, 56.6%, 60.1% and 61.5% of placebo, CZP 200 mg Q2W and CZP 400 mg Q4W patients were employed. By week 24, employed CZP patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05). Within the home, by week 24, CZP patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05). CZP patients also reported fewer days with reduced household productivity or days lost for participation in family, social and leisure activities. Improvements with CZP were seen as early as week 4 and continued to week 24. CONCLUSIONS: CZP treatment significantly improved productivity at paid work and within the home, and resulted in greater participation in social activities for PsA patients. TRIAL REGISTRATION NUMBER: NCT01087788. BMJ Publishing Group 2015-01 2014-06-18 /pmc/articles/PMC4283690/ /pubmed/24942382 http://dx.doi.org/10.1136/annrheumdis-2014-205198 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Clinical and Epidemiological Research
Kavanaugh, A
Gladman, D
van der Heijde, D
Purcaru, O
Mease, P
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title_full Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title_fullStr Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title_full_unstemmed Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title_short Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
title_sort improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
topic Clinical and Epidemiological Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283690/
https://www.ncbi.nlm.nih.gov/pubmed/24942382
http://dx.doi.org/10.1136/annrheumdis-2014-205198
work_keys_str_mv AT kavanaugha improvementsinproductivityatpaidworkandwithinthehouseholdandincreasedparticipationindailyactivitiesafter24weeksofcertolizumabpegoltreatmentofpatientswithpsoriaticarthritisresultsofaphase3doubleblindrandomisedplacebocontrolledstudy
AT gladmand improvementsinproductivityatpaidworkandwithinthehouseholdandincreasedparticipationindailyactivitiesafter24weeksofcertolizumabpegoltreatmentofpatientswithpsoriaticarthritisresultsofaphase3doubleblindrandomisedplacebocontrolledstudy
AT vanderheijded improvementsinproductivityatpaidworkandwithinthehouseholdandincreasedparticipationindailyactivitiesafter24weeksofcertolizumabpegoltreatmentofpatientswithpsoriaticarthritisresultsofaphase3doubleblindrandomisedplacebocontrolledstudy
AT purcaruo improvementsinproductivityatpaidworkandwithinthehouseholdandincreasedparticipationindailyactivitiesafter24weeksofcertolizumabpegoltreatmentofpatientswithpsoriaticarthritisresultsofaphase3doubleblindrandomisedplacebocontrolledstudy
AT measep improvementsinproductivityatpaidworkandwithinthehouseholdandincreasedparticipationindailyactivitiesafter24weeksofcertolizumabpegoltreatmentofpatientswithpsoriaticarthritisresultsofaphase3doubleblindrandomisedplacebocontrolledstudy